Development of population and Bayesian models for applied use in patients receiving cefepime

1 Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA; Northwestern Memorial Hospital, Chicago, IL, USA; Midwestern University Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA;

2 Children's Hospital Los Angeles and University of Southern California, Los Angeles, CA, USA;

3 UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia; Royal Brisbane and Women's Hospital, Brisbane, Australia;

4 UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, University of Queensland, Australia;

5 UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Australia; Royal Brisbane and Women's Hospital, Brisbane, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, University of Queensland, Au;

6 Indiana University Health, Indianapolis, IN, USA;

7 Antiviral Pharmacology Laboratory, University of Nebraska Medical Center (UNMC) Center for Drug Discovery, UNMC Oma